Formulary guidance and transparency from P&T to point of care

Trends That Matter for Orphan Drugs

Posted by Matt Breese on Jan 12, 2017

Find me on:

In our weekly Trends that Matter series, we provide engaging infographics from healthcare influencers to highlight general trends affecting the pharmaceutical industry. This week's featured pharma topic is orphan drugs. These high-priced drugs treat rare diseases, serving a small group of patients. 

Many healthcare experts predict the sale of orphan drugs will continue to rise. In fact, "Orphan drugs set to be 20.2% of worldwide prescription sales by 2020 (excluding generics,)" reports Andreas Hadjivasiliou, Analyst at EvaluatePharma.

However, orphan drug manufacturers may encounter regulatory challenges. According to Lisa Urquhart, Editor at EP Vantage:

"With increasing scrutiny over drug cost, particularly among lawmakers, and payers becoming more vocal in their desire to manage escalating drug bills, orphan drug developers will have to ensure that the drugs they produce continue to be innovative and can help reduce the overall healthcare budget." 

View the infographic below, created by Igeahub to see the projected sales of orphan drugs in 2018. 

Orphan Drugs.png

Subscribe to the MMIT blog for more insights on trends affecting pharmaceutical manufacturers, providers and payers.

Subscribe for Weekly Trends that Matter

Topics: Industry Trends